ANALYSIS OF THE FACTORS DETERMINING THE EFFICIENCY OF TREATMENT IN PATIENTS WITH NON-INVASIVE INTRADUCTAL BREAST CANCER
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-3-2020-g.9248Keywords:
adjuvant treatment, local recurrence, non-invasive intraductal breast cancer, Paget’s disease, surgical treatmentAbstract
Currently, clinicians’ opinions regarding the optimal scope of surgical and adjuvant treatment of patients with breast non-invasive intraductal cancer (DCIS) are ambiguous. Since the presence of DCIS increases the risk of invasive malignant neoplasm developing by 2–8 times, clarification of this issue is indispensable. Aim: to analyze the long-term treatment results of patients with DCIS of the mammary gland, depending on the clinical and pathological characteristics, receptor status, tumor grade, type and characteristics of surgical and adjuvant treatment. Object and methods: the clinical records of 79 patients (aged 22–60 years) with DCIS of the breast were analyzed. In accordance with current standards for the breast carcinoma diagnosis, all the patients underwent a complete mammological instrumental examination; the diagnosis was confirmed by histopathological examination; the resection margin was assessed intraoperatively; tumor tissues were examined postoperatively. All the patients underwent surgical treatment (organ-preserving or mastectomy with one-stage reconstruction); 38.0% of patients received postoperative radiation therapy (SOD 40–50 Gy); patients with tumors expressing steroid hormone receptors were given hormone therapy with tamoxifen. The median follow-up period was 91.8 months. Results: in the majority cases, the patients were 40–50 years old (63.3%), the tumor nodes measured 1.0–7.0 cm (68.4%), receptor status was ER+PR+/–HER2/neu– (86.1%) and differentiation grade was G3 (58.3%). In 6.3%, DCIS was associated with Paget’s disease. During a follow-up period of 36–152 months, local relapses were found in 8.9% (seven cases); one patient died. The local recurrence development was associated with the patients’ young age (<30 years), multicentric tumor, it’s triple negative molecular type, and the lack of adjuvant treatment. Conclusions: the necessity to evaluate and exclude DCIS spread to the nipple is demonstrated. In high-risk cases, patients with DCIS of the mammary gland should have surgical excision with clean resection margins (R0), if necessary, mastectomy, with adjuvant radiation and (if indicated) hormone therapy.
References
Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review 1975–2008. Bethesda: National Cancer Institute (http://seer.can- cer.gov/csr/1975–2008/).
Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with DCIS of the breast in the population-based surveillance, epidemiology and end-results program. Arch Intern Med 2000; 160 (7): 953–8.
Fisher ER, Land SR, Saad RS, et al. Pathologic variables predictive of breast cancer events in patients with DCIS. Am J Clin Pathol 2007; 128 (1): 86–91.
Yen MF, Tabar L, Vitak B, et al. Quantifying the potential problem of overdiagnosis of DCIS in breast cancerscreening. Eur J Cancer 2003; 39 (12): 1746–54.
Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of DCIS in women undergoing screening mammography. JNCI 2002; 94 (20): 1546–54.
May DS, Lee NC, Richardson LC, et al. Mammography and breast cancer detection by race and Hispanic eth- nicity: results from a national program (United States). Cancer Causes Control 2000; 11 (8): 695–705.
Formenti SC, Arslan AA, Pike MC. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. JNCI: Journal of the National Cancer Institute 2011; 103 (22): 1723 (https://doi.org/10.1093/jnci/djr406).
Bellamy CO, McDonald C, Salter DM, et al. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993; 24 (1): 16–23.
Ajisaka H, Tsugawa K, Noguch M, et al. Histological subtypes of ductal carcinoma in situ of the breast. Breast Cancer 2002; 9 (1): 55–61.
Lester SC, Connolly JL, Amin MB. College of American Pathologists protocol for the reporting of ductal carcinoma in situ. Arch Pathol Lab Med 2009; 133: 13–14.
Groen EJ, Elshof LE, Visser LL, et al. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast 2017; 31: 274–83.
Kerlikowske K, Barclay J, Grady D, et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 1997; 89 (1): 76–82.
Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 2001; 93 (23): 1811–17.
Claus EB, Stowe M, Carter D. Oral contraceptives and the risk of ductal breast carcinoma in situ. Breast Cancer Res Treat 2003; 81 (2): 129–36.
Duffy SW, Dibden A, Michalopoulos D, et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol 2016; 17 (1): 109–14.
Ballard LJ, Ballard GR. High-grade ductal carcinoma in situ: an overview for the radiologist. J Am Osteopath Coll Radiol 2013; 2 (1): 18–25.
Nadrljanski MM, Markovic BB, Milosevic ZC. Breast ductal carcinoma in situ: morphologic and kinetic MRI findings. Iran J Radiol 2013; 10 (2): 99–102.
Kim JA, Son EJ, Youk JH, et al. MRI findings of pure ductal carcinoma in situ: kinetic characteristics compared according to lesion type and histopathologic factors. AJR 2011; 196 (6): 1450–56.
Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with DCIS treated by lumpectomy. J Natl Cancer Inst 2003; 95 (22): 1692–702.
Bijker N, Meijnen P, Peterse JL, et al. Breast conserving treatment with or without radiotherapy in DCIS: 10-year results of EORTC randomized phase 3 trial 10853-A study by the EORTC Breast Cancer Cooperative Group and the EORTC Radiotherapy Group. J Clin Oncol 2006; 24 (21): 3381–7.
Meretoja TJ, Heikkila PS, Salmenkivi K, et al. Outcome of patients with DCIS and sentinel node biopsy. Ann Surg Oncol 2012; 19 (7): 2345–51.
Lyons JM, Stempel M, Van Zee KJ, et al. Axillary node staging for microinvasive breast cancer: is it justified? Ann Surg Oncol 2012; 19 (11): 3416–21.
Shah DR, Canter RJ, Khatri VP, et al. Utilization of sentinel lymph node biopsy in patients with DCIS undergoing mastectomy. Ann Surg Oncol 2012. doi:10.1245/s10434-012-2539-4.
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305 (6): 569–75.
Parikh U, Chhor CM, Mercado CL. Ductal carcinoma in situ: the whole truth. AJR 2018; 210 (2): 246–25.
